Borealis Biosciences Funding: $150M Raised, Series A (2024)
Borealis Biosciences is based in Vancouver, Canada. It has raised $150M in total funding. Latest round: Series A.
Borealis Biosciences funding overview
Borealis Biosciences is based in Vancouver, Canada. Borealis Biosciences has raised $150M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in December 2024. The round record for Borealis Biosciences runs through 2024; nothing later has been disclosed. Investors on record include Versant Ventures, Novartis, Westlake Village BioPartners. 3 distinct backers are named across the disclosed rounds.
Borealis Biosciences at a glance
Total raised
$150M
Latest round
Series A
Latest round date
December 2024
Headquarters
Vancouver, Canada
Notable investors
Versant Ventures, Novartis, Westlake Village BioPartners
Frequently asked about Borealis Biosciences funding
How much has Borealis Biosciences raised?
Borealis Biosciences has raised $150M in total disclosed funding across the rounds on record.
Who has invested in Borealis Biosciences?
Versant Ventures, Novartis, Westlake Village BioPartners are named among the investors backing Borealis Biosciences.
What was the latest Borealis Biosciences funding round?
The most recent disclosed round is a Series A, announced in December 2024.
Where is Borealis Biosciences based?
Borealis Biosciences is based in Vancouver, Canada.
When did Borealis Biosciences last raise?
The last disclosed Borealis Biosciences round closed in December 2024 at Series A.
Totals shown for Borealis Biosciences aggregate every disclosed round on file. To see how that compares, browse the companies in Vancouver and the investors behind them below.
